Zacks.com on MSN14h
GILD Stock Down on Report of Cut in HIV Prevention SpendingGilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services department is mulling cuts to federal HIV prevention funding ...
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback